Drug Patents owned by Pfizer

1. Drug name - CIBINQO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(11 years from now)

CN105008362B PFIZER As Associated Janus Kinase (Jak) Inhibitor Of Pyrrolo [2 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN105008362A PFIZER Pyrrolo [2, 3-D] Pyrimidine Derivative Used As James Related Kinase (As Jak) Inhibitor
Feb, 2034

(11 years from now)

CN107089985B PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

CN107089985A PFIZER As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives
Feb, 2034

(11 years from now)

IN201506803P1 PFIZER Pyrrolo [2 3 D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

IN329290B PFIZER Pyrrolo [2, 3, D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421B1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP3290421A1 PFIZER Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921A1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

EP2958921B1 PFIZER Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives Feb, 2034

(11 years from now)

Drugs and Companies using ABROCITINIB ingredient

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

2. Drug name - DAURISMO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8148401 PFIZER Benzimidazole derivatives
Jan, 2031

(8 years from now)

US10414748 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate
Apr, 2036

(13 years from now)

CN101687841B PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

CN101687841A PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

IN288288B PFIZER A Compound That Is 1-[(2R,4R)-2-(1Hbenzimidazol- 2-Yl)- 1-Methyl-Piperidin- 4-Yl]-3-(4- Cyanophenyl)Urea Or A Pharmaceutically Acceptable Salt Thereof
Jun, 2028

(5 years from now)

IN200908059P1 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860B9 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860B1 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP2170860A2 PFIZER Benzimidazole Derivatives
Jun, 2028

(5 years from now)

EP3666768A1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3666768B1 PFIZER Preparation Process Of A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate; A Crystalline Form Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Imidazole Complex (1:1)
Apr, 2036

(13 years from now)

EP3286176B1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

EP3286176A1 PFIZER Crystalline Forms Of 1-((2R,4R)-2-(1H-Benzo[D]Imidazol-2-Yl)-1-Methylpiperidin-4-Yl)-3-(4-Cyanophenyl)Urea Maleate
Apr, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431597 PFIZER Benzimidazole derivatives Jun, 2028

(5 years from now)

US11168066 PFIZER Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate Apr, 2036

(13 years from now)

Drugs and Companies using GLASDEGIB MALEATE ingredient

Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

3. Drug name - IBRANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6936612 PFIZER 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

US7208489 PFIZER 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Jan, 2023

(3 months from now)

USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

US10723730 PFIZER Solid forms of a selective CDK4/6 inhibitor
Feb, 2034

(11 years from now)

CN105008357A PFIZER Solid State Form Of Selective Cdk4/6 Inhibitor
Jul, 2020

(2 years ago)

CN101906104B PFIZER 2-(Pyridin-2-Yl Amino)-Pyrido [2, 3-D] Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101001857A PFIZER 2-(Pyridine-2-Yl Amido)-Pyridino[2,3-D]Pyrimidine-7-Ketone
Jan, 2023

(3 months from now)

CN102295643B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101906104A PFIZER 2-(Pyrid-2-Ylamino)-Pyridino[2,3-D] Pyrimidine-7-One
Jan, 2023

(3 months from now)

CN102295643A PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

CN101001857B PFIZER 2-(Pyridine-2-Ylamio)-Pyrido[2,3-D]Pyrimidin-7-Ketone
Jan, 2023

(3 months from now)

IN218291B PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

IN200401733P1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido(2,3-D)Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124B1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP1470124A1 PFIZER 2-(Pyridin-2-Ylamino)-Pyrido 2,3-D]Pyrimidin-7-Ones
Jan, 2023

(3 months from now)

EP2958916A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP3431475B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP3431475A1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

EP2958916B1 PFIZER Solid Forms Of A Selective Cdk4/6 Inhibitor
Feb, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7456168 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones Jan, 2023

(3 months from now)

US11065250 PFIZER Solid dosage forms of palbociclib May, 2036

(13 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: Palbociclib for hr-pos. her2-neg. advanced or metastatic breast cancer in combo with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men, or with fulvestrant in pts with disease progression after endocrine therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
125MG TABLET;ORAL Prescription

4. Drug name - LORBRENA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8680111 PFIZER Macrocyclic derivatives for the treatment of diseases
Mar, 2033

(10 years from now)

US10420749 PFIZER Crystalline form of lorlatinib free base
Jul, 2036

(13 years from now)

CN104169286A PFIZER Macrocyclic Derivative For Treating Proliferative Diseases
Feb, 2033

(10 years from now)

CN104169286B PFIZER Macrocyclic Derivative For Treating Proliferative Diseases
Feb, 2033

(10 years from now)

IN201407205P4 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

IN298989B PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953B9 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953B1 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP2822953A1 PFIZER Macrocyclic Derivatives For The Treatment Of Proliferative Diseases
Feb, 2033

(10 years from now)

EP3328867B9 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

EP3328867A1 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

EP3328867B1 PFIZER Crystalline Form Of Lorlatinib Free Base
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020376 PFIZER Crystalline form of lorlatinib free base Jul, 2036

(13 years from now)

Drugs and Companies using LORLATINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription

5. Drug name - TALZENNA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420650 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Jul, 2029

(6 years from now)

US8012976 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
Oct, 2029

(7 years from now)

US10189837 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

US8735392 PFIZER Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Oct, 2031

(9 years from now)

CN104478875B PFIZER Poly (Adp-Ribose) Polymerase (Parp) Dihydropyridine And Phthalazinone Inhibitors
Jul, 2029

(6 years from now)

CN102171214A PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

CN102171214B PFIZER Poly (Adp-Ribose) Polymerase (Parp) And Dihydro Pyridine Phthalocyanine And Triazine Ketone Inhibitor
Jul, 2029

(6 years from now)

CN104478875A PFIZER Dihydro Pyridine Phthalocyanine Triazine Ketone Inhibitor Of Poly (Adp-Ribose) Polymerase (Parp)
Jul, 2029

(6 years from now)

CN103282365A PFIZER Crystals Of (8S, 9R) -5-(4 - (-8 - Fluorophenyl) -9-(1-Methyl - -1H-1, 2, 4-Triazole - -5 - Group) - 9, -8 - Dihydro - -2H - Pyrido [4 3, 2-De] Phthalazine -3 (7H) - Ketone Tosylate
Oct, 2031

(9 years from now)

CN103282365B PFIZER Crystalline Toluenesulfonate Of (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phthalazine-3-(7H)-One
Oct, 2031

(9 years from now)

IN298469B PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adpribose) Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650A2 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650B1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650B9 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2326650A4 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2767537A1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2767537B1 PFIZER Dihydropyridophthalazinone Inhibitors Of Poly(Adp-Ribose)Polymerase (Parp)
Jul, 2029

(6 years from now)

EP2630146A1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

EP2630146B1 PFIZER Crystaline (8S,9R)-5-Fluoro-8-(4-Fluorophenyl)-9-(1-Methyl-1H-1,2,4-Triazol-5-Yl)-8,9-Dihydro-2H-Pyrido[4,3,2-De]Phtalazin-3(7H)-One Tosylate Salt
Oct, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9820985 PFIZER Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) Jul, 2029

(6 years from now)

Drugs and Companies using TALAZOPARIB TOSYLATE ingredient

Treatment: Treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (brca)-mutated (gbrcam) human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription
EQ 0.75MG BASE CAPSULE;ORAL Prescription
EQ 1MG BASE CAPSULE;ORAL Prescription

6. Drug name - TOVIAZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6858650 PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines
Jul, 2022

(2 months ago)

CN1215045C PFIZER Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound
Nov, 2020

(1 year, 10 months ago)

CN1390194A PFIZER Stable Salts Of New Derivatives Of 3, 3-Diphenyl Propylamine Compound
Nov, 2020

(1 year, 10 months ago)

EP1481964B1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1230209B3 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1690536A3 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

EP1690536B1 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

EP1230209B1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1230209A2 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1481964A1 PFIZER Stable Salts Of Novel Derivatives Of 3,3-Diphenylpropylamines
Nov, 2020

(1 year, 10 months ago)

EP1690536A2 PFIZER Use Of R-(+)-2-(3-Diisopropylamino-1-Phenylpropyl)-4-Hydroxy-Methyl-Phenylisobutyric Acid Ester Hydrogenfumarate For The Treatment Of Urinary Incontinence And Other Spasmogenic Disorders
Nov, 2020

(1 year, 10 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858650

(Pediatric)

PFIZER Stable salts of novel derivatives of 3,3-diphenylpropylamines Jan, 2023

(3 months from now)

US7807715 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US8088398 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US8501723 PFIZER Pharmaceutical compositions comprising fesoterodine Jun, 2027

(4 years from now)

US7807715

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

US8501723

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

US8088398

(Pediatric)

PFIZER Pharmaceutical compositions comprising fesoterodine Dec, 2027

(5 years from now)

Drugs and Companies using FESOTERODINE FUMARATE ingredient

Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
4MG TABLET, EXTENDED RELEASE;ORAL Prescription
8MG TABLET, EXTENDED RELEASE;ORAL Prescription

7. Drug name - TROXYCA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685443 PFIZER Sequestering subunit and related compositions and methods Jul, 2025

(2 years from now)

US7815934 PFIZER Sequestering subunit and related compositions and methods Dec, 2027

(5 years from now)

Drugs and Companies using NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1.2MG;10MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
2.4MG;20MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
3.6MG;30MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
4.8MG;40MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
7.2MG;60MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
9.6MG;80MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

8. Drug name - VIZIMPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7772243 PFIZER 4-phenylamino-quinazolin-6-yl-amides
Aug, 2028

(5 years from now)

CN1972688B PFIZER 4-Anilino-Quinazoline-6-Yl-Amide Compound
Apr, 2025

(2 years from now)

CN1972688A PFIZER 4-Phenylamino-Quinazolin-6-Yl-Amides Compounds
Apr, 2025

(2 years from now)

IN244837B PFIZER 4-Phenylamino-Quinazolin-6-Yl-Amides And A Pharmaceutical Composition Comprising The Same
Apr, 2025

(2 years from now)

IN200606238P1 PFIZER 4-Phenylamino-Quinazolin-6-Yl-Amides
Apr, 2025

(2 years from now)

EP1746999A1 PFIZER 4-Phenylamino-Quinazolin-6-Yl-Amides
Apr, 2025

(2 years from now)

EP1746999B1 PFIZER 4-Phenylamino-Quinazolin-6-Yl-Amides
Apr, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623883 PFIZER 4-phenylamino-quinazolin-6-yl-amides May, 2025

(2 years from now)

Drugs and Companies using DACOMITINIB ingredient

Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
15MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription
45MG TABLET;ORAL Prescription

9. Drug name - XELJANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

IN241773B PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200200588P1 PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

EP1235830B1 PFIZER Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PFIZER Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339A1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

More Information on Dosage
Strength Dosage Availability
EQ 1MG/ML BASE SOLUTION;ORAL Prescription

10. Drug name - XELJANZ XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6965027 PFIZER Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate
Mar, 2023

(5 months from now)

USRE41783 PFIZER Pyrrolo[2,3-D]pyrimidine compounds
Dec, 2025

(3 years from now)

CN1195755C PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1409712A PFIZER Pyrrolo [2, 3-D] Pyrimidine Compound
Nov, 2020

(1 year, 10 months ago)

CN1325498C PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

CN1596257A PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

IN241773B PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200200588P1 PFIZER Pyrrolo[2,3-D] Pyrimidine Compounds
Nov, 2020

(1 year, 10 months ago)

IN200401095P1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

IN218212B PFIZER Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN200607324P1 PFIZER 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

IN251800B PFIZER 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation
Nov, 2022

(a month from now)

EP1382339A1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1235830A2 PFIZER Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1235830B1 PFIZER Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors
Nov, 2020

(1 year, 10 months ago)

EP1382339B1 PFIZER Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives
Nov, 2020

(1 year, 10 months ago)

EP1451192A1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

EP1451192B1 PFIZER Novel Crystalline Compound
Nov, 2022

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10639309 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

US9937181 PFIZER Tofacitinib oral sustained release dosage forms Mar, 2034

(11 years from now)

Drugs and Companies using TOFACITINIB CITRATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 22MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.